↓ Skip to main content

Cochrane Database of Systematic Reviews

Neuroprotection for treatment of glaucoma in adults

Overview of attention for article published in this source, February 2013
Altmetric Badge

Readers on

106 Mendeley
Neuroprotection for treatment of glaucoma in adults
Published by
John Wiley & Sons, Ltd, February 2013
DOI 10.1002/14651858.cd006539.pub3
Pubmed ID

Sena, Dayse F, Lindsley, Kristina


Glaucoma is a heterogeneous group of conditions involving progressive damage to the optic nerve, deterioration of retinal ganglion cells and ultimately visual field loss. It is a leading cause of blindness worldwide. Open angle glaucoma (OAG), the commonest form of glaucoma, is a chronic condition that may or may not present with increased intraocular pressure (IOP). Neuroprotection for glaucoma refers to any intervention intended to prevent optic nerve damage or cell death.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 106 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 <1%
United States 1 <1%
Unknown 104 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 23 22%
Other 15 14%
Student > Master 14 13%
Student > Ph. D. Student 14 13%
Student > Doctoral Student 11 10%
Other 24 23%
Unknown 5 5%
Readers by discipline Count As %
Medicine and Dentistry 58 55%
Agricultural and Biological Sciences 12 11%
Biochemistry, Genetics and Molecular Biology 5 5%
Nursing and Health Professions 3 3%
Pharmacology, Toxicology and Pharmaceutical Science 3 3%
Other 16 15%
Unknown 9 8%